Boehringer Ingelheim and Hydra Biosciences to collaborate on new treatments for renal diseases and disorders
Hydra will receive an undisclosed upfront payment, research funding, milestone payments and royalties
Boehringer Ingelheim and Hydra Biosciences have entered into a worldwide research collaboration and licensing agreement with a primary focus on renal diseases and disorders.
Cambridge, MA, US-based Hydra Biosciences focuses on transient receptor potential (TRP) channel modulation and Boehringer Ingelheim will aim to identify small-molecule TRP inhibitors.
Under the terms of the agreement, Boehringer Ingelheim is responsible for the global development and commercialisation of the inhibitors that come from the collaboration and Hydra will receive an undisclosed upfront payment, additional research funding, and potentially milestone payments and tiered royalties on future product sales.
Michel Pairet, Senior Corporate Vice President of Research and Non-clinical Development at Boehringer Ingelheim, said the agreement 'reflects the importance and value Boehringer Ingelheim places in developing strong research partnerships to discover new treatments for renal diseases and related disorders'.
Russell Herndon, President and CEO of Hydra Biosciences, added: 'This partnership provides an excellent opportunity to maximise the potential of novel targets that may offer meaningful improvements in the treatment of chronic kidney diseases and other related diseases and disorders.'
This is the second collaboration between the two companies which last year researched and developed small-molecule TRPC4/5 inhibitors for the treatment of central nervous system (CNS) diseases and disorders.